[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n R67NWvkte8mkvIJg4lIy5BzuIF3uijg4fJTrniGYDNkBLScsLqeAnY8n/z4t8JiQ\n SRxL8MW6nWhsGittYrmSVg==\n\n', u'0000950129-04-006727.txt : 20040901\n', u'0000950129-04-006727.hdr.sgml : 20040901\n', u'20040901152413\nACCESSION NUMBER:\t\t0000950129-04-006727\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t3\nCONFORMED PERIOD OF REPORT:\t20040901\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20040901\nDATE AS OF CHANGE:\t\t20040901\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tMANNKIND CORP\n\t\tCENTRAL INDEX KEY:\t\t\t0000899460\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tPHARMACEUTICAL PREPARATIONS [2834]\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t000-50865\n\t\tFILM NUMBER:\t\t041011093\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t28903 NORTH AVE PAINE\n\t\tCITY:\t\t\tVALENCIA\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t91355\n\t\tBUSINESS PHONE:\t\t6617755300\n', u'\n', u'\n', u'8-K\n', u'1\n', u'v01595e8vk.htm\n', u'MANNKIND CORPORATION - DATED SEPTEMBER 1, 2004\n', u'\n', u'e8vk', u'\n', u' PAGEBREAK ', u'\n', u'Table of Contents', u'\n', u'\n', u'\n', u'\n', u'UNITED STATES', u'\nSECURITIES AND EXCHANGE COMMISSION', u'\n', u'WASHINGTON, D.C. 20549', u'\n', u'\n', u'FORM 8-K', u'\n', u'CURRENT REPORT\n\n\n\n', u'Pursuant to Section\xa013 or 15(d) of the', u'\nSecurities Exchange Act of 1934\n\n\n\n', u'Date of Report (Date of earliest event reported): September\xa01, 2004\n\n\n', u'MannKind Corporation', u'\n', u'(Exact name of registrant as specified in its charter)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Delaware', u'\n(State or other jurisdiction of', u'\nincorporation)\n', u'\n', u'\xa0', u'\n', u'000-50865', u'\n(Commission File Number)\n', u'\n', u'\xa0', u'\n', u'13-3607736', u'\n(IRS Employer', u'\nIdentification No.)', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'28903 North Avenue Paine', u'\nValencia, California', u'\n(Address of principal executive offices)\n', u'\n', u'\xa0', u'\n', u'91355', u'\n(Zip Code)', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'Registrant\x92s Telephone Number, Including Area Code: ', u'(661)\xa0775-5300', u'\n', u'N/A', u'\n', u'(Former name or former address, if changed since last report)', u'\n', u'Check the appropriate box below if the Form 8-K is intended to simultaneously\nsatisfy the filing obligation of the registrant under any of the following\nprovisions (', u'see ', u'General Instruction A.2. below):\n\n\n\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'o', u' Written communications pursuant to Rule\xa0425 under the Securities Act (17 CFR 230.425)', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'o', u' Soliciting material pursuant to Rule\xa014a-12 under the Exchange Act (17 CFR 240.14a-12)', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'o', u' Pre-commencement communications pursuant to Rule\xa014d-2(b) under\nthe Exchange Act (17 CFR 240.14d-2(b))', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'o', u' Pre-commencement communications pursuant to Rule\xa013e-4(c) under\nthe Exchange Act (17 CRF 240.13e-4(c))', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\n', u' TOC ', u'\n', u'TABLE OF CONTENTS', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Item\xa02.02 Results of Operations and Financial Condition', u'\n', u'Item\xa09.01 Financial Statements and Exhibits', u'\n', u'SIGNATURE', u'\n', u'EXHIBIT INDEX', u'\n', u'Exhibit 99.1', u'\n', u'\n', u'\n', u' /TOC ', u'\n', u'\n', u'Table of Contents', u'\n', u'Section\xa02 \x97 Financial Information', u'\n', u' link2 "Item&nbsp;2.02 Results of Operations and Financial Condition" ', u'\n', u'\n', u'Item\xa02.02 Results of Operations and Financial Condition', u'\n', u'On September\xa01, 2004 MannKind Corporation issued a press release announcing its\nfinancial results for the second quarter of 2004. A copy of the press release\nis furnished as Exhibit\xa099.1 to this report and is incorporated herein by\nreference.\n\n\n\n', u'Section\xa09 \x97 Financial Statements and Exhibits', u'\n', u' link2 "Item&nbsp;9.01 Financial Statements and Exhibits" ', u'\n', u'\n', u'Item\xa09.01 Financial Statements and Exhibits', u'\n', u'\n', u'\n', u'\n', u'(c)', u'\n', u'\xa0', u'\n', u'Exhibits.', u'\n', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'99.1\n', u'\n', u'\xa0', u'\n', u'Press Release of MannKind Corporation dated September\xa01, 2004, reporting\nMannKind\x92s financial results for the second quarter of 2004.', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'Table of Contents', u'\n', u'\n', u' link1 "SIGNATURE" ', u'\n', u'\n', u'SIGNATURE', u'\n', u'\xa0\xa0\xa0\xa0\xa0Pursuant to the requirements of the Securities Exchange Act of 1934, the\nregistrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized.\n\n\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'MANNKIND CORPORATION', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'By:\xa0\xa0', u'\n', u'/s/ RICHARD L. ANDERSON\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Name:\xa0\xa0', u'\n', u'Richard L. Anderson\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Title:\xa0\xa0', u'\n', u'Chief Financial Officer\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Dated: September\xa01, 2004\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'Table of Contents', u'\n', u'\n', u' link1 "EXHIBIT INDEX" ', u'\n', u'\n', u'EXHIBIT INDEX', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Number', u'\n', u'\xa0', u'\n', u'Description', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'99.1\n', u'\n', u'\xa0', u'\n', u'Press Release of\nMannKind Corporation\ndated September\xa01,\n2004, reporting\nMannKind\x92s financial\nresults for the second\nquarter of 2004.', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\xa0\n', u'\n', u'\n', u'\n', u'\n', u'EX-99.1\n', u'2\n', u'v01595exv99w1.htm\n', u'EXHIBIT 99.1\n', u'\n', u'exv99w1', u'\n', u' PAGEBREAK ', u'\n', u'\xa0', u'\n', u'\n', u'Exhibit\xa099.1\n\n\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Company Contact:', u'\n', u'\n', u'\xa0', u'\n', u'Investor Relations:', u'\n', u'\n', u'\n', u'Dick Anderson\n', u'\n', u'\xa0', u'\n', u'Ina McGuinness or Bruce Voss', u'\n', u'\n', u'\n', u'Chief Financial Officer\n', u'\n', u'\xa0', u'\n', u'Lippert/Heilshorn & Associates', u'\n', u'\n', u'\n', u'661-775-5302\n', u'\n', u'\xa0', u'\n', u'310 691-7100', u'\n', u'\n', u'\n', u'danderson@mannkindcorp.com\n', u'\n', u'\xa0', u'\n', u'imcguinness@lhai.com', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'MANNKIND REPORTS SECOND QUARTER FINANCIAL RESULTS', u'\n', u'VALENCIA, Calif. (September\xa01, 2004) \x96 MannKind Corporation (Nasdaq: MNKD)', u',\ntoday reported financial results for the second quarter and six months ended\nJune\xa030, 2004.\n\n\n', u'For the second quarter of 2004, total operating expenses were $18.4\xa0million,\ncompared with $13.2\xa0million in the second quarter of 2003. Research &\nDevelopment (R&D) expenses increased by $5.0\xa0million to $14.3\xa0million primarily\ndue to the increased expenses associated with expanded clinical trials and\nrelated support for the Company\x92s Technosphere\xae Insulin product. General and\nadministrative (G&A) expenses increased by $0.2\xa0million to $4.1\xa0million. The\nnet loss for the second quarter of 2004 was $18.2\xa0million versus a net loss of\n$13.1\xa0million in the second quarter of 2003. Net loss per share was $0.91 in\nthe second quarter of 2004 compared with a net loss of $0.79 for the comparable\n2003 period. Net loss per share, when calculated on a pro forma basis to give\neffect to the conversion of preferred stock into common stock upon the closing\nof MannKind\x92s initial public offering on August\xa02, 2004, was $0.73 in the\nsecond quarter of 2004.\n\n\n', u'For the first six months of 2004, operating expenses totaled $35.0\xa0million\ncompared with $33.6\xa0million in the first half of 2003. R&D expenses were $27.1\nmillion, up $6.2\xa0million, again related primarily to the expansion of clinical\ntrials of MannKind\x92s Technosphere\xae Insulin program. G&A expenses were $7.8\nmillion, a decrease of $4.9\xa0million from the first half of 2003, when the\nCompany consolidated its California operations into a single facility.\n\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'For the first half of 2004, the net loss was $34.7\xa0million, versus a net loss\nof $33.4\xa0million in the first half of 2003.\n\n\n', u'Cash, cash equivalents and marketable securities at June\xa030, 2004 were $41.3\nmillion, compared with $55.9\xa0million at December\xa031, 2003. Subsequent to June\n30, 2004, MannKind completed its initial public offering, resulting in net\nproceeds of approximately $83.6\xa0million, including $4.0\xa0million in proceeds\nfrom the exercise of the underwriter\x92s over-allotment option.\n\n\n\n', u'About MannKind Corporation', u'\n', u'MannKind focuses on the discovery, development and commercialization of\ntherapeutic products for diseases including diabetes, cancer, inflammatory and\nautoimmune diseases. The Company\x92s lead product, the Technosphere\xae Insulin\nSystem, which is currently in late Phase II clinical trials for the treatment\nof diabetes, consists of a proprietary dry powder Technosphere\xae formulation of\ninsulin that is inhaled into the deep lung using MannKind\x92s MedTone\x99 inhaler.\nEarly indications show MannKind\x92s proprietary Technosphere\xae Insulin System\x92s\nperformance characteristics, convenience and ease of use have the potential to\nchange the way diabetes is treated. For more information on MannKind\nCorporation and its technology, visit www.mannkindcorp.com.\n\n\n', u'Forward-Looking Statements', u'\nThis press release contains forward-looking statements, including statements\nrelated to our clinical trials and product candidates. Words such as\n\x93believes,\x94 \x93anticipates,\x94 \x93plans,\x94 \x93expects,\x94 \x93intend,\x94 \x93will,\x94 \x93goal\x94 and\nsimilar expressions are intended to identify forward-looking statements. These\nforward-looking statements are based upon our current expectations.\nForward-looking statements involve risks and uncertainties. Actual results and\nthe timing of events could differ materially from those anticipated in such\nforward-looking statements as a result of these risks and uncertainties, which\ninclude, without limitation, risks related to the progress, timing and results\nof clinical trials, intellectual property matters, difficulties or delays in\nobtaining regulatory approval, manufacturing our lead product candidate,\ncompetition from other pharmaceutical or biotechnology companies, our ability\nto obtain additional financing to support our operations and other risks\ndetailed in our filings with the SEC, including our Registration Statement on\nForm S-1. You are cautioned not to place undue reliance on these\nforward-looking statements, which speak only as of the date of this press\nrelease. All forward-looking statements are qualified in their entirety by this\ncautionary statement, and MannKind undertakes no obligation to revise or update\nany forward-looking statements to reflect events or circumstances after the\ndate of this release.\n\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'MannKind Corporation', u'\nConsolidated Statements of Operations', u'\n(Unaudited)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(In thousands, except share and per share amounts)', u'\n', u'\xa0', u'\n', u'Three Months Ended', u'\n', u'\xa0', u'\n', u'Six Months Ended', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'June 30,', u'\n', u'\xa0', u'\n', u'June 30,', u'\n', u'\xa0', u'\n', u'June 30,', u'\n', u'\xa0', u'\n', u'June 30,', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Revenue', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'OPERATING EXPENSES:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Research & development', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'14,311', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,321', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'27,110', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'20,884', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'General & administrative', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,071', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,903', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,840', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'12,710', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'18,382', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'13,224', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'34,950', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'33,594', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Loss from operations', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(18,382', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(13,224', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(34,950', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(33,594', u'\n', u')', u'\n', u'\n', u'\n', u'Interest income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'123', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'119', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'221', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'204', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'14', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'75', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(33', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Loss before provision for income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(18,245', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(13,088', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(34,654', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(33,423', u'\n', u')', u'\n', u'\n', u'\n', u'Income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net loss', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(18,245', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(13,088', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(34,654', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(33,423', u'\n', u')', u'\n', u'\n', u'\n', u'Deemed dividend related to beneficial\nconversion feature of convertible preferred\nstock', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(875', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(612', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(875', u'\n', u')', u'\n', u'\n', u'\n', u'Accretion on redeemable preferred stock', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(63', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(60', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(123', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net loss applicable to common stockholders', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(18,241', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(14,026', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(35,326', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(34,421', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net loss per share:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic and diluted', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(0.91', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(0.79', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(1.77', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(2.01', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic and diluted \x96 pro forma', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(0.73', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(1.44', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Shares used to compute basic and diluted\nnet loss per share:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic and diluted', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'19,975', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,760', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'19,975', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,117', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic and diluted \x97 pro forma', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'24,907', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'24,562', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Condensed balance sheet data (in thousands):', u'\n', u'\xa0', u'\n', u'6/30/04', u'\n', u'\xa0', u'\n', u'12/31/03', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Cash, cash equivalents and marketable securities', u'\n', u'\xa0', u'\n', u'$', u'\n', u'41,260', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'55,945', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Working capital', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'35,865', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'49,097', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'110,778', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'125,876', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Deferred compensation and other liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'130', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'404', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Redeemable convertible preferred stock', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,248', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,188', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Deficit accumulated during the development stage', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(401,625', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(366,971', u'\n', u')', u'\n', u'\n', u'\n', u'Total stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'97,352', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'111,577', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\xa0\n', u'\n', u'\n', u'\n', u'\n', u'GRAPHIC\n', u'3\n', u'v01595v0159500.gif\n', u'GRAPHIC\n', u'\nbegin 644 v01595v0159500.gif\nM1TE&.#EAV`!(`//CX^KJZO\'Q\\?CX^/_[\\*"@I("`@/\\```#_\nM`/__````__\\`_P#______RP`````V`!(```(_@#_"1PH*L6B$W[C*ULJK7\nMKTD3T*(USZ\'!6>*B`[5(2LR"\\OU+@GKTY0ER`MS)]=T\\I`^V_HW,B_@M3[+*KOU]"Q#AW(U>_C\nMY-BI/E.\\:S%"D)^[_DM/3)!7[45^LZN?^IOQ\\=VP&', u')\\Y1I%UM749I)5@.D1/*P=$]R5!M6"(\nMGBGWA>EF1%BZYA]$4>)XGB*SO:EG0YQ%I^5#UDWY5(U[%FKA@%A]2', u'O8GB%W::', u"$,U#)*'U;#M/FR]U2^1`0XY;[D7:$MJ0MKF=N]2IM>REZE-TFF*O*9IM\nM=2^T)Q5ERBPVMB704\\AN*;!#%]Y[9E6US`(PI_8661)OC:7))8ZFW/80K;59\nMV&62+\\73EDN+)OA/*_9>9)U#;?W5", u'7+*__P%3\\F+4%H/ROB.]B*M`\\UC;U=!V9OWP$XO^H_%(K>-UC&$QHG_XMZ:V4,+/#J=J&.:^`K4.*:G\nMMZP2IL[=>\']71**D"\'E\\\nM#U.3Z]OI#,B1Y\'%-$>Z`6MLUB$', u'QI&>UH:FFKL\\)2I4\'.):J$C!D"@M@GYY"Q69",4;_J5$\nM6$M5ZZA&1S!*9DT#@=\\2L75%\\\'FD>YM!C-95Q($US\nMW&(2X+ZZH(]\\>8)?6>HAI18BJYB6A-\'G%ME$FM%O;UG!VUIF6;"$],I.L/F4\nMF#!%G!4^12=C;&%7)HE&%JH1BO=9Y1NMJ,$ZMI!DS[PCZ5YD3\')][IT"_O\'C\nM6AH7R+]$!7F_*F0+`6;)6K2%@3\'$UO38Y#Y)YA"?[FR(06OEEVB\\"0/>!SK-H5,6%3R\nMB#8HJ\']M*)38QBR6-%9:*,!.E"[X,U&U+SDFJJC:2>=$G_M7`VX23-SDS)\nM0E2B$X9NI"\'Y_#?\'K5%QIJ02E"!I5$Q]C,=&I]5@RF]E"![(W\nM/*W))9\'ARE=12+#80329H+I8XRY:&\'K.JBV&1=E0$%F/9B6`\'F/YSRGEJ;5_\nM1I*5K3,/2+7&TKU.CT)B.5.LC#,T3NWL5N2C_FL.1W.94!6MC>"M:A4I&E6JD\\)H=JI:T&WN1(29G6O>\nMEB#3DE"UM\'LE>QG/-\'M3K#45\\YG>DM=-#5Q3U90\'+[TX]KTKNA[&^,775\\&&\nMB_C%3U$NM3!=,68[`5:2L8PED6F))U[W3?!ZMN*KNCW$\'I&"#58DK*(C\'8M2\nM$@G*11V370XG9VYK\\EI$$%.F_YI80=1U*T;BQ!NXO?@T)\\JD1IJ$%17?1Q,PGR\\EI\nM&H#AM!?^@ODTBQHS)T06P^4SXT:M&^&+F[-C58U$R\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']